Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2

Novo Nordisk’s $1 billion bet that it had found a cannabinoid CB1 receptor blocker that could reduce weight while avoiding the psychiatric effects that capsized Sanofi’s Acomplia faces questions after the company revealed mid-stage headline results.